Improving outcomes for patients with chronic hepatitis B

Current Gastroenterology Reports

Volumn 9, Issue 1, 2007, Pages 14-22

  Gish, Robert G ^a  

^a CALIFORNIA PACIFIC MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

16ALPHA BROMOEPIANDROSTERONE; 2 AMINO 9 (1 PHOSPHONOMETHOXYCYCLOPROPYLMETHYL)PURINE BIS(PIVALOYLOXYMETHYL) ESTER; ADEFOVIR; ADEFOVIR DIPIVOXIL; ALAMIFOVIR; ALPHA2A INTERFERON; ALPHA2B INTERFERON; ANTIVIRUS AGENT; BAM 205; CLEVUDINE; EHT 899; EMTRICITABINE; EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; ENTECAVIR; HEPATITIS B VACCINE; HEPATITIS B(E) ANTIGEN; INACTIVATED VACCINE; INTERFERON; LAMIVUDINE; LB 803380; MIV 210; PEGINTERFERON; PLACEBO; PRADEFOVIR; RECOMBINANT VACCINE; TELBIVUDINE; TENOFOVIR; TENOFOVIR DISOPROXIL; UNCLASSIFIED DRUG; UNINDEXED DRUG; VIRUS DNA;

ANTIVIRAL ACTIVITY; CHRONIC HEPATITIS; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DRUG MECHANISM; DRUG POTENCY; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; INFECTION SENSITIVITY; LIVER CANCER; LIVER CARCINOGENESIS; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER DISEASE; LIVER FAILURE; LIVER TRANSPLANTATION; MONOTHERAPY; MORTALITY; NEPHROTOXICITY; NONHUMAN; OSTEOPOROSIS; REVIEW; RISK REDUCTION; SEROCONVERSION; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT; VACCINATION;

ADENINE; ANTIVIRAL AGENTS; DRUG RESISTANCE, VIRAL; GUANINE; HEPATITIS B VACCINES; HEPATITIS B, CHRONIC; HUMANS; INTERFERON ALFA-2A; INTERFERON ALFA-2B; LAMIVUDINE; NUCLEOSIDES; PHOSPHONIC ACIDS; POLYETHYLENE GLYCOLS; PYRIMIDINONES; TREATMENT OUTCOME; VIRAL LOAD;

EID: 33947661970     PISSN: 15228037     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11894-008-0016-9     Document Type: Review

References (52)

1. Lavanchy D: Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures. J Viral Hepat 2004, 11:97-107.
2. Gish RG, Gadano AC: Chronic hepatitis B: current epidemiology in the Americas and implications for management. J Viral Hepat 2006, in press.
3. Ganem D, Prince AM: Hepatitis B virus infection - natural history and clinical consequences. N Engl J Med 2004, 350:1118-1129.
4. World Health Organization: Hepatitis B. Fact Sheet No. 204. http://www.who.int/mediacentre/factsheets/fs204/en. Accessed August 2, 2006.
5. Dienstag JL, Cianciara J, Karayalcin S, et al.: Durability of serologic response after lainivadine treatment of chronic hepatitis B. Hepatology 2003, 37:748-755.
6. Fung SK, Wong F, Hussain M, Lok AS: Sustained response after a 2-year course of lamivudine treatment of hepatitis B e antigen-negative chronic hepatitis B. J Viral Hepat 2004, 11:432-38.
7. Bartholomeusz A, Locarnini SA: Antiviral drug resistance: clinical consequences and molecular aspects. Semin Liv Dis 2006, 162-170.
8. Fung SK, Andreone P, Han SH, et al.: Adefovir-resistant hepatitis B can be associated with viral rebound and hepatic decompensation. J Hepatol 2005, 43:937-943.
9. Hoofnagle JH, DiBisceglie AM: The treatment of chronic viral hepatitis. N Engl J Med 1997, 336:347-356.
10. Cihlar T, Lin DC, Pritchard JB, et al.: The antiviral nucleotide analogs cidofovir and adefovir are novel substrates for human and rat renal organic anion transporter 1. Mol Pharmacol 1999, 56:570-580.
11. Hadziyannis SJ, Tassopoulos NC, Heathcote EJ, et al.: Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B. N Engl J Med 2005, 352:2673-2681.
12. U.S. Food and Drug Administration: Center for Drug Evaluation and Research: CDER priority drug and biologic approvals in calendar year 2005. http://www.fda.gov/cder/rdmt/InternetPriorityO5.htm. Accessed August 4, 2006.
13. World Health Organization: Hepatitis B vaccines. WHO position paper. Weekly epidemiological record 2004, 79:255-263. http://www.who.int/wer. Accessed August 4, 2006.
14. Zuckerman JN: Protective efficacy, immunotherapeutic potential, and safety of hepatitis B vaccines. J Med Virol 2006, 78:169-177.
15. Chang MH, Chen CJ, Lai MS, et al.: Universal hepatitis B vaccination in Taiwan and the incidence of hepatocellular carcinoma in children. Taiwan Childhood Hepatoma Study Group. N Engl J Med 1997,336:1855-59.
16. Lok ASF, McMahon BJ: Chronic hepatitis B: update of recommendations. Hepatology 2004, 39:857-861.
17. Zarski JP, Marcellin P, Leroy V, et al.: Characteristics of patients with chronic hepatitis B in France: predominant frequency of HBe antigen negative cases. J Hepatol 2006, 45:355-360.
18. Fattovich G: Natural history of hepatitis B. J Hepatol 2003, 39:S50-S58.
19. Manesis EK, Papatheodoridis GV, Sevastianos V, et al.: Significance of hepatitis B viremia levels determined by a quantitative polymerase chain reaction assay in patients with hepatitis B e antigen-negative chronic hepatitis B virus infection. Am J Gastroenterol 2003, 98:2261-2267.
20. Keeffe EB, Dieterich DT, Han SHB, et al.: A treatment algorithm for the management of chronic hepatitis B virus infection in the United States: an update. Clin Gastroenterol Hepatol 2006, 4:936-962.
21. Chen CJ, Yang HI, Su J, et al.: Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA 2006, 295:65-73.
22. Iloeje UH, Yang HI, Su J, et al.: Predicting cirrhosis risk based on the level of circulating hepatitis B viral load. Gastroenterology 2006, 130:678-686.
23. Chen G, Lin W, Shen F, et al.: Past HBV viral load as predictor of mortality and morbidity from HCC and chronic liver disease in a prospective study. Am J Gastroenterol 2006, 101:1797-1803.
24. Yuen MF, Yuan HJ, Wong DKH, et al.: Prognostic determinants for chronic hepatitis B in Asians: therapeutic implications. Gut 2005, 54:1610-1614.
25. Mommeja-Marin H, Mondou E, et al.: Serum HBV DNA as a marker of efficacy during therapy for chronic HBV infection: analysis and review of the literature. Hepatology 2003, 37:1309-1319.
26. Liaw YF, Sung JJY, Chow WC, ct al.: Lamivudine for patients with chronic hepatitis B and advanced liver disease. N Engl J Med 2004, 351:1521-1531.
27. Schiff E, Lai CL, Hadziyannis S, et al.: Adefovir dipivoxil 10 mg (ADV) for the treatment of chronic hepatitis B in patients pre-liver transplantation with lamivudine-rcsistant HBV [abstract]. Hepatology 2003, 38:161A.
28. Locarnini S, Hatzakis A, Heathcote J, et al.: Management of antiviral resistance in patients with chronic hepatitis B. Antivir Ther 2004, 9:679-693.
29. Lau GKK, Piratvisuth T, Luo KX, et al.: Peginterferon Alfa-2a, lamivadine, and the combination for HBeAg-positive chronic hepatitis B. N Engl J Med 2005, 352:2682-2694.
30. Marcellin P, Lau GKK, Bonino F, et al.: Peginterferon Alfa-2a alone, lamivudine alone, and the two in combination in patients with HBeAg-negative chronic hepatitis B. N Engl J Med 2004, 351:1206-1217.
31. Dienstag JL, Schiff ER, Wright TL, et al.: Lamivudine as initial treatment for chronic hepatitis B in the United States. N Engl J Med 1999, 341:12S6-1263.
32. Tassopoulos NC, Volpes R, Pastore G, et al.: Efficacy of lamivudine in patients with hepatitis B e antigen-negative/hepatitis B virus DNA-positive (precore mutant) chronic hepatitis B. Hepatology 1999, 29:889-896.
33. Marcellin P, Chang TT, Lim SG, et al.: Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B. N Engl J Med 2003, 348:808-816.
34. Hadziyannis SJ, Tassopoulos NC, Heathcote EJ, et al.: Adefovir dipivoxil for the treatment of hepatitis B e antigen-negative chronic hepatitis B. N Engl J Med 2003, 348:800-807.
35. Marcellin P, Chang T, Lim S, et al.: Increasing serologic, virologic, and biochemical response over time to adefovir dipivoxil (ADV) 10 mg in RBeAg(+) chronic hepatitis B patients. J Hepatol 2005, 42(Suppl 2):31-32.
36. Seifer M, Hamatake RK, Colonno RJ, Standring DN: In vitro inhibition of hepadnavirus polymerases by the triphosphates of BMS-200475 and lobucavir. Antimicrob Agents Chemother 1998; 42:3200-3208.
37. Chang TT, Gish RG, de Man R, et al.: A comparison of entecavir and lamivudine for HBeAg-positvie chronic hepatitis B. N Engl J Med 2006, 354:1001-1010.
38. Lai CL, Shouval D, Lok AS, et al.: Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B. N Engl J Med 2006, 354:1011-1020.
39. Gish RG, Chang TT, de Man RA, et al.: Entecavir results in substantial virologic and biochemical improvement and HBeAg seroconversion through 96 weeks of treatment in HBeAg(+) chronic hepatitis B patients (study ETV-022) [abstract]. Hepatology 2005, 42(Suppl 1):267A.
40. Poordad F, Dieterich DT, Min AD, et al.: Continued virologic improvement through 96 weeks of entecavir treatment in HBeAg(-) chronic hepatitis B patients (study ETV-027). Presented at Digestive Diseases Week. Los Angeles, CA. May 20-25, 2006; abstract T1851.
41. Lai CL, Leung N, Teo EK, et al.: A 1-year trial of telbivudine, lamivudine, and the combination in patients with hepatitis Be antigen-positive chronic hepatitis B. Gastroenterology 2005, 129:528-536.
42. Lai CL, Gane E, Liaw YF, et al.: Telbivudine (LdT) vs lamivudine for chronic hepatitis B: first-year results from the international phase III GLOBE trial [abstract]. Hepatology 2005, 42(Suppl 1):748A
43. Standring DN, Seifer M, Patty A, et al.: HBV resistance determination from the telbivudine GLOBE registration trial. Presented at the 41st Annual meeting of the European Association for the Study of the Liver. Vienna, Austria. April 26-30, 2006; abstract S14.
44. Lai CL, Gane E, Hsu CW, et al. Two-year results from the GLOBE trial in patients with hepatitis B: greater clinical and antiviral efficacy for telbivudine (LdT) vs. lamivudine. Hepatology 2006, 44(Suppl 1): 222A.
45. Locarnini S: Relevance of HBV mutations in severity and progression of chronic hepatitis B. J Gastroenterol Hepatol 2004, 196:S108-S112.
46. Gilead Sciences: Hepsera (adefovir dipivoxil). Prescribing information. Foster City, CA: Gilead; April 2006.
47. Borroto-Esoda K, Arterburn S, Snow A, et al.: Final analysis of virological outcomes and resistance during 5 years of adefovir dipivoxil monotherapy in HBeAg-negative patients. Presented at the 41st Annual meeting of the European Association for the Study of the Liver. Vienna, Austria: April 26-30, 2006; abstract 483.
48. Colonno R, Rose R, Levine S, et al.: Entecavir two year resistance update: no resistance observed in nucleoside-naïve patients and low frequency resistance emergence in lamivudine refractory patients [abstract]. Hepatology 2005, 42(Suppl 1):573A.
49. Colonno RJ, Rose RE, Pokornowski K, et al. Assessment at three years shows high barrier to resistance is maintained in entecavir-treated nucleoside-naive patients while resistance emergence increases over time in lamivudine-refractory patients. Hepatology 2006, 44(Suppl 1):229A-230A.
50. Perrillo R, Schiff E, Yoshida E, et al.: Adefovir dipivoxil for the treatment of lamivudine-resistant hepatitis B mutants. Hepatology 2000, 2:129-134.
51. Sherman M, Yurdaydin C, Sollano J, et al.: Entecavir for treatment of lamivudine-refractory, HBeAg-positive chronic hepatitis B. Gastroenterology 2006, 130:2039-2049.
52. Fung SK, Chae SB, Fontana RJ, et al.: Virologic response and resistance to adefovir in patients with chronic hepatitis B. Hepatology 2006, 44:283-290.